HIV-related Insomnia and Inflammation

Hiv Clinical Trial

Official title:

Treating Insomnia to Reduce Inflammation in HIV

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04721067
• Other study ID #: 1R21MH127206-01
• Secondary ID: 1R21MH127206-01
• Status: Completed
• Phase: N/A
• Start date: December 2, 2021
• Est. completion date: March 15, 2024

Study information

• Verified date: April 2024
• Source: Indiana University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This randomized trial will determine the effects of internet cognitive behavioral therapy on measures of systemic inflammation in HIV-positive people receiving antiretroviral therapy.

Description:

The primary objective of this pilot trial is to evaluate the effects of cognitive behavioral therapy for insomnia (CBT-I) on changes in circulating levels of hsCRP at 24 weeks in virologically-suppressed, HIV-positive adults with insomnia, defined as having an Insomnia Severity Index (ISI) score ≥ 11. Secondary objectives include comparing changes in hsCRP at 12 weeks, changes in other circulating inflammation biomarkers (IL-6, sCD14, sCD163, CD14+CD16+ monocytes) at both 12 and 24 weeks, and ISI scores and other self-reported patient outcomes at both 12 and 24 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: March 15, 2024
• Est. primary completion date: March 15, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• HIV-1 infection, documented as listed clinically in the participant's electronic medical record by any of the following tests: (1) any licensed rapid HIV test, (2) HIV enzyme test kit at any time prior to study entry, (3) at least one detectable HIV-1 antigen, or (4) at least one detectable plasma HIV-1 RNA viral load.

• Age equal to or greater than 18 years.

• Ongoing receipt of stable antiretroviral therapy of any kind for at least 180 days prior to the date of the HIV-1 RNA value determining eligibility.

• HIV-1 RNA level < 75 copies/mL at Screening.

NOTE: There are no CD4 cell count eligibility criteria for this trial.

-ISI score = 11 at Screening.

NOTE: Use of sleeping aids/medications is permitted as long as the ISI score criterion is met.

Exclusion Criteria:

• Inability to complete written, informed consent.

• Incarceration at the time of any study visit.

• Active suicidality at Entry, as determined by the patient's HIV provider or social worker following a positive response (1, 2, or 3) to PHQ-9 Item #9 and a positive response (yes) to one or more of the three questions (for Question #3, the previous attempt must be within the past 10 years) on the Patient Suicidality Form (see Appendix).

• Diagnosed disease or process, besides HIV infection, associated with increased systemic inflammation (including, but not limited to, systemic lupus erythematosus, inflammatory bowel diseases, or other collagen vascular diseases).

NOTE: Hepatitis B or C co-infections are NOT exclusionary, but treatment for hepatitis C cannot be provided during study participation.

• End stage renal disease requiring renal replacement therapy (dialysis, transplantation).

• Known or suspected malignancy requiring systemic treatment within 180 days of the Entry Visit.

NOTE: Localized treatment for skin cancers is not exclusionary.

-Therapy for serious medical illnesses within 14 days prior to the Entry Visit.

NOTE: Therapy for serious medical illnesses that overlaps with a study visit will result in postponement of that study visit until the course of therapy is completed; postponement outside of the allowed study visit timeframe will result in study discontinuation.

• Pregnancy or breastfeeding during the course of the study.

• Receipt of investigational agents, cytotoxic chemotherapy, systemic immunosuppressive therapies, systemic glucocorticoids (of any dose), or anabolic steroids at the Entry Visit.

NOTE: Physiologic testosterone replacement therapy or topical steroids is not exclusionary. Inhaled/nasal steroids are not exclusionary as long as the participant is not also receiving HIV protease inhibitors.

• Active drug use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements.

• History of bipolar disorder or a psychotic disorder, including schizophrenia.

NOTE: Depressive disorders are not exclusionary.

• Current sleep disorder diagnosis other than insomnia disorder (e.g., sleep apnea).

• Have a schedule requiring a bedtime earlier than 8:00pm or later than 2:00am or arising time earlier than 4:00am or later than 10:00am (thus preventing adoption of SHUTi interventions).

Related Conditions & MeSH terms

• Hiv
• Inflammation
• Insomnia
• Sleep Initiation and Maintenance Disorders

Intervention

Device:
• SHUTi
SHUTi is the empirically supported, internet CBT-I that is fully accessible via tablets and smartphones. It uses a self-guided, fully automated, interactive, multimedia format to deliver six 45-minute sessions, the structure and content of which mirror traditional face-to-face CBT-I. Session content includes sleep restriction, stimulus control, sleep hygiene, cognitive restructuring, and relapse prevention. SHUTi is enhanced through a variety of interactive features, including personalized goal setting, graphical feedback based on inputted symptoms, animations and illustrations to enhance comprehension, quizzes to test user knowledge, patient vignettes, and video-based expert explanation. Across sessions, patients also receive tailored sleep recommendations and feedback based on the sleep diary data they enter into the program.

Behavioral:
• Sleep Education/Hygiene
A research assistant (RA) will deliver the active control procedures. During the first 4 weeks, the RA will have two calls with each control participant - one 45-minute call on insomnia education (including their HIV provider's role in its management) and one 45-minute call on sleep hygiene practices. To end the first call, the RA will email or mail a list of local behavioral health services to patients and will encourage them to follow-up with their HIV provider. We will then notify the HIV provider, which will encourage them to address their patient's insomnia and provide the same list of local services.

Locations

Country	Name	City	State
United States	Indiana University Infectious Diseases Research	Indianapolis	Indiana

Sponsors (2)

Lead Sponsor	Collaborator
Indiana University	National Institute of Mental Health (NIMH)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in hsCRP levels at 24 weeks	Circulating high sensitivity C-reactive protein levels will be measured	Baseline and 24 weeks
Secondary	Change is IL-6 levels at 12 and 24 weeks	Circulating interleukin-6 levels will be measured	Baseline, 12 and 24 weeks
Secondary	Change is sCD14 levels at 12 and 24 weeks	Circulating soluble CD14 levels will be measured	Baseline, 12 and 24 weeks
Secondary	Change in sCD163 levels at 12 and 24 weeks	Circulating soluble CD163 levels will be measured	Baseline,12 and 24 weeks
Secondary	Change in CD14+CD16+ monocytes at 12 and 24 weeks	Circulating intermediate monocytes as defined by flow cytometric evaluation for CD14+CD16+ monocytes will be measured	Baseline,12 and 24 weeks
Secondary	Change in hsCRP levels at 12 weeks	Circulating high sensitivity C-reactive protein levels will be measured	Baseline and 12 weeks
Secondary	Change in Insomnia Severity Index (ISI) at 12 and 24 weeks	ISI questionnaire scores will be measured	Baseline, 12, and 24 weeks
Secondary	Change in Pittsburgh Sleep Quality Index (PSQI) at 12 and 24 weeks	PSQI questionnaire scores will be measured	Baseline, 12, and 24 weeks
Secondary	Change in Dysfunctional Beliefs and Attitudes about Sleep (DBAS-16) at 12 and 24 weeks	DBAS-16 questionnaire scores will be measured	Baseline, 12, and 24 weeks
Secondary	Change in Patient Health Questionnaire-9 (PHQ-9) at 12 and 24 weeks	PHQ-9 questionnaire scores will be measured	Baseline, 12, and 24 weeks
Secondary	Change in Hopkins Symptom Checklist (SCL-20) at 12 and 24 weeks	SCL-20 questionnaire scores will be measured	Baseline, 12, and 24 weeks
Secondary	Change in Generalized Anxiety Disorder-7 (GAD-7) at 12 and 24 weeks	GAD-7 questionnaire scores will be measured	Baseline, 12, and 24 weeks
Secondary	Change in PROMIS Fatigue Short Form at 12 and 24 weeks	PROMIS questionnaire scores will be measured	Baseline, 12, and 24 weeks
Secondary	Change in Alcohol Use Disorders Identification Test (AUDIT) at 12 and 24 weeks	AUDIT questionnaire scores will be measured	Baseline, 12, and 24 weeks
Secondary	Change in Short Form-36 (SF-36) Health Survey at 12 and 24 weeks	SF-36 questionnaire scores will be measured	Baseline, 12, and 24 weeks
Secondary	Change in sleep medication use at 12 and 24 weeks	Concomitant medications for sleep will be recorded	Baseline, 12, and 24 weeks
Secondary	Change in insomnia treatment satisfaction at 12 and 24 weeks	Insomnia treatment satisfaction scores will be measured	Baseline, 12, and 24 weeks